CoChat

Anti‐PDGF‐B monoclonal antibody reduces liver fibrosis development

Ogawa, Shinji, Ochi, Takashi, Shimada, Hideaki, Inagaki, Kazuyuki, Fujita, Isami, Nii, Aisuke, Moffat, Mark A., Katragadda, Madan, Violand, Bernard N., Arch, Robert H., Masferrer, Jaime L. · 2010 · Hepatology Research
Cited by 62

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Aim: To evaluate the usefulness of a platelet‐derived growth factor (PDGF)‐B specific monoclonal antibody (mAb) as a therapeutic agent to treat chronic liver fibrosis. Methods: Liver fibrosis was induced in ICR mice by bile duct ligation (BDL) or BALB/c mice by weekly injection of concanavalin A (ConA) for 4 or 8 weeks. A mAb specific for mouse and human PDGF‐B chain, AbyD3263, was generated, tested in vitro and administered twice a week throughout the experimental period. Results: AbyD3263 showed neutralizing activity against mouse and human PDGF‐B chain in cell‐based assays, as measured in vitro by inhibition of phosphorylation of PDGF receptor β and proliferation of hepatic stellate cells induced by PDGF‐BB. The half life of AbyD3263 in mice exceeded 7 days and dosing of animals twice a week resulted in constant plasma levels of the mAb. Induction of liver fibrosis by BDL and ConA resulted in elevated levels of alanine aminotransferase (ALT) in plasma and hydroxyproline in the liver. Treatment with AbyD3263 did not modify ALT levels, but significantly reduced hydroxyproline content in the liver with a maximum reduction of 39% and 54% in the BDL and ConA models, respectively, compared to controls. Conclusios: Consistent with the notion that PDGF‐BB plays an important role in the progression of liver fibrosis, AbyD3263 exhibits efficacy in pre‐clinical disease models suggesting that pharmacological inhibition of PDGF‐B chain may be a therapeutic approach to treat liver fibrosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1872-034x.2010.00718.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 62

Metadata

Authors
Ogawa, S., Ochi, T., Shimada, H., Inagaki, K., Fujita, I., Nii, A., Moffat, M. A., Katragadda, M., Violand, B. N., Arch, R. H., & Masferrer, J. L.
Venue
Hepatology Research
Publisher
Wiley
Published
2010-09-28
Volume
40
Issue
11
Pages
1128-1141
ISSN
  • 1386-6346 (ISSN-L)
  • 1872-034X
OpenAlex
W1921041546
Cited by
62
References
2
FWCI
3.58
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti‐PDGF‐B monoclonal antibody reduces liver fibrosis development. https://app.cochat.ai/papers/10.1111/j.1872-034x.2010.00718.x
The paper
Ogawa, S., Ochi, T., Shimada, H., Inagaki, K., Fujita, I., Nii, A., Moffat, M. A., Katragadda, M., Violand, B. N., Arch, R. H., & Masferrer, J. L. (2010). Anti‐PDGF‐B monoclonal antibody reduces liver fibrosis development. Hepatology Research. https://doi.org/10.1111/j.1872-034x.2010.00718.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.